Abivax reports promising abx464 phase 2a one-year maintenance results in rheumatoid arthritis
Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have now reached the first year of treatment and all achieved at least an ACR201 , with 19 and 12 patients achieving ACR50 and ACR70 respectively
Long-term safety profile (50mg ABX464 once daily + MTX) favorable and consistent with previous observations
The induction and maintenance results support further clinical development of ABX464 in RA and potentially other rheumatology indications
The clinical induction and maintenance data in ulcerative colitis and rheumatoid arthritis underpin the potential of ABX464 to address a broad range of chronic inflammatory diseases.
In G7 countries, the market for ulcerative colitis, Crohn’s disease and rheumatoid arthritis is expected to grow to approximately USD 50B in 2026
More information in the Press Release